In a prostate TRAMP mouse model, apigenin administration significantly decreases prostate tumor volumes and completely abolishes cancer cell metastasis by inhibiting IKK activation, which in turn leads to the suppression of NF-κB activation [77]. Here, NFKB1 is linked to cancer.